BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Uncategorized » The beta cell as a paradigm for advances in inositide research

The beta cell as a paradigm for advances in inositide research

Inositides are involved in regulating the insulin release from the pancreatic beta cell. New findings are published in Advances in Biological Regulation in September 2012.

Inositides take an active part in regulating many vital processes in all cells in the organism. Depending on its primary function, cells have a specific footprint of what inositides they contain.

Over the last 20 years, there has been a growing understanding of the molecular processes within the insulin-producing beta cells under both healthy and diabetic conditions. Along with understanding the beta cells comes the knowledge on the role inositides play in the regulation of insulin release.

Professor Per-Olof Berggren’s research group in Karolinska Institutet has made three major advances in this field:

  1. Ins(1,4,5)P3 mobilizes calcium ions, Ca2+, from intracellular stores. This is important for Ca2+ dynamics and thereby pancreatic beta cell function and survival.
  2. A defect in generation of IP7 (also called 5-PP-InsP5) may lead to a reduction in the first phase of insulin release. Reduced first phase  is an early indication of type 2 diabetes
  3. When beta-cells release insulin, they signal back to the cell to produce more insulin through a PI3K signalling pathway. This feedback mechanism is important to maintain beta cell concentration of insulin, which thereby keep blood sugar at normal levels.

Read more:

The pancreatic beta cell as a pardigm for advances in inositide research. Barker CJ, Berggren PO. Advances in Biological Regulation. 2012 Sep;52(3):361-8

February 17, 2013 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved